Objectives: To evaluate the effects of long-term milnacipran treatment in fibromyalgia patients. Methods: Patients completing a previous milnacipran study were eligible to participate in this long-term (up to 3.25 y), open-label study. After washout, dose escalation, and 8 weeks of stable-dose treatment (100 mg/d), patients received flexible doses of milnacipran (50 to 200 mg/d) for the remainder of the study. Safety evaluations included adverse events and vital signs. Clinical measures included weekly recall pain (visual analog scale [VAS]), Patient Global Disease Status (PGDS), and the Short Form-36 Health Survey (SF-36, including the Physical Component Summary [PCS] and Mental Component Summary scores). Cohort analyses were conducted to assess the effects of milnacipran over varying periods of time.
F ibromyalgia (FM) is a complex pain disorder that affects approximately 2% to 4% of the general population, occurring more frequently in women than men. 1 In addition to pain, patients with FM often experience multiple debilitating symptoms, including fatigue, stiffness, sleep disturbances, depressed mood, cognitive difficulties, as well as decreased physical and mental functioning. 2, 3 The exact causes of FM are unknown, but many factors probably contribute to the etiology of this disorder, including environmental and biological stressors, psychological illness or distress, and genetic predisposition. [4] [5] [6] In addition, the current evidence strongly suggests that pain and related symptoms (eg, mood, sleep, and fatigue) result from changes in the central nervous system. Such changes include deficits in pain inhibition that involve serotonergic, noradrenergic, and opioidergic pathways. FM is a chronic disorder 7, 8 in which patients experience waxing and waning of symptoms over time. 9, 10 Although FM is not degenerative, a patient's quality of life may deteriorate if symptoms are left untreated. Uncontrolled pain and fatigue can contribute to a downward cycle of reduced physical activity, inability to perform daily tasks, increased social isolation, missed work, and long-term disability. 9, 10 Effective long-term FM treatments are therefore needed to help patients manage their symptom burden throughout the course of their illness.
Given the chronic nature of FM and the ongoing need for treatment, identifying safe and well-tolerated treatments with durable clinical efficacy is an important therapeutic goal. Three medications are currently approved by the US Food and Drug Administration for the management of FM: pregabalin, duloxetine, and milnacipran. In large, randomized, double-blind, placebo-controlled trials ranging from 3 to 6 months, patients receiving these medications had significantly greater improvements over placebo in multiple symptom domains. 11, 12 The effects of longer treatment with these 3 drugs have also been reported, with sustained improvements in pain and other FM symptoms found in patients receiving 3 months of double-blind pregabalin treatment followed by 12 months of open-label treatment, 13 12 months of double-blind duloxetine treatment, 14, 15 and in patients receiving 12 to 15 months of doubleblind milnacipran treatment. [16] [17] [18] To evaluate long-term effects of milnacipran in patients with FM, participants from placebo-controlled and extension studies with milnacipran were subsequently enrolled in an open-label, flexible-dose study in which they received up to an additional 3.25 years of milnacipran treatment. To our knowledge, this is the first study to evaluate a FM pharmacotherapy for such an extended length of time. The aim of this study was to assess the longterm safety and tolerability of milnacipran for the treatment of FM, as well as the durability of its effects on pain, global status, and functioning.
MATERIALS AND METHODS

Overview
This was an open-label, flexible-dosing, phase 3 study conducted in 110 study centers in the United States and Canada to evaluate the long-term safety (up to 3.25 y) of milnacipran for the treatment of FM. Enrollment began on October 10, 2006, and the study was completed on February 4, 2010. The study protocol was approved by the Institutional Review Board at each study center. This clinical study was conducted in accordance with the ethical principles as stated in the Declaration of Helsinki, Code of Federal Regulations, International Conference on Harmonisation Guidances on General Considerations for Clinical Trials, and Good Clinical Practice. All patients provided written informed consent to participate in the study.
Patients
Patients who completed a previous milnacipran study, had been participating in a previous study when it was terminated by the sponsor (ie, administratively discontinued), or were currently participating in another milnacipran study were eligible for enrollment in this study.
This study included patients, aged 18 to 70 years, from 5 placebo-controlled trials [19] [20] [21] [22] [23] and 2 extension studies 16, 17 who met the American College of Rheumatology 1990 criteria for FM. 24 Patients were excluded from the present study if they had significant psychiatric illness (as determined by self-report or investigator judgment), a Beck Depression Inventory (BDI) total score >25, 25 or significant risk of suicide based on investigator judgment or BDI item score for suicidal ideation. Other exclusion criteria included abuse of alcohol, benzodiazepines, or other drugs, based on investigator judgment; clinically significant cardiovascular, respiratory, endocrine, or genitourinary disease; active liver or peptic ulcer disease; renal impairment; autoimmune disease; systemic infection; cancer or current chemotherapy; life expectancy <3 years; history of inflammatory bowel or celiac sprue; women who were pregnant or breastfeeding.
Patients were also excluded if they received another experimental agent within 30 days before screening or concomitant therapy with digitalis, MAO-A or MAO-B inhibitors, other dual reuptake inhibitors (eg, venlafaxine and duloxetine), or selective serotonin reuptake inhibitors (eg, escitalopram, fluoxetine, and paroxetine) at any time during the study. Triptan use was allowed for acute migraine treatment, as were butalbital, aspirin/acetaminophen, and caffeine for headache treatment. Nonsteroidal antiinflammatory agents and centrally acting analgesics for chronic or central pain, including anticonvulsants, muscle relaxants, herbal remedies, and opioids, were also allowed. Hypnotics, including sedating antihistamines and chloral hydrate, were allowed for the treatment of insomnia; benzodiazepines and anxiolytics were also allowed; antiemetics were permitted for the treatment of nausea. Other antidepressants were permitted with caution if they did not have serotonin or norepinephrine reuptake inhibition properties (eg, bupropion and mirtazapine). Physical modalities such as routine physical therapy, chiropractic manipulation, massage therapy, acupuncture, transcutaneous electrical nerve stimulation, regional nerve blocks, joint injections, trigger and tender point injections, lidocaine, and opioid patches were allowed.
Study Design
This study included screening and washout (2 wk), dose escalation (2 wk), stable-dose treatment with milnacipran (100 mg/d; 8 wk), and flexible-dose, open-label treatment with milnacipran (50 to 200 mg/d) to end of study (up to 3.25 y). For patients who enrolled directly from a previous milnacipran study, screening was conducted at the final visit of that previous study. Washout was not required for these patients if they did not receive study drug or any prohibited medication for at least 2 weeks before screening (1 wk for patients in studies that included a down-titration or discontinuation phase 22, 23 ).
After washout, dosages were escalated to milnacipran 100 mg/d (50 mg bid) as follows: 12.5 mg/d (day 1), 25 mg/d (days 2 to 3), 37.5 mg/d (days 4 to 5), 50 mg/d (days 6 to 8), 75 mg/d (days 9 to 11), and 100 mg/d (days 12 to 14). After stable-dose treatment with milnacipran 100 mg/d for 8 weeks, dosages could be escalated to a maximum of 200 mg/d during the flexible-dose, open-label period if FM symptoms were not effectively controlled, or decreased to a minimum of 50 mg/d if patients were unable to tolerate the 100 mg/d dosage.
Assessments were conducted at screening, beginning of dose escalation (baseline), at the beginning and end of stable-dose treatment, during the open-label treatment period (at 3, 6, 9, 12, 16 to 18, 20, 24, and 30 mo) , and at the final study visit. Time of the final study visit varied among patients, ranging from 36 to 38 months after baseline. This allowed patients to continue receiving milnacipran until the drug became commercially available in 2010. At this time, the study was administratively terminated.
Outcome Measures
The primary aim of this study was to evaluate the safety and tolerability of long-term milnacipran treatment in patients with FM. Treatment-emergent adverse events (AEs) were defined as SRd that were not present before the first dose of open-label study drug or that increased in severity during the study. Vital signs (ie, supine blood pressure, supine heart rate, and weight) and clinical laboratory tests results (ie, hematology, chemistry, and urinalysis) were also monitored for safety. BDI was assessed to monitor changes in depressive symptoms.
No primary or secondary efficacy endpoints were defined in this study as it was conducted primarily to ascertain tolerability and safety. However, the effects of long-term milnacipran treatment on pain and other patient-reported outcomes were evaluated. 26 Recall pain (24 h and weekly) was assessed by using 100 mm visual analog scales (VAS) with anchors of 0 = "no pain" to 100 = "worst possible pain." Global improvement was assessed with the Patient Global Impression of Change (PGIC) in which patients answered a single item (Since the start of this follow-up study, overall my fibromyalgia is) using a scale ranging from 1 = "very much improved" to 7 = "very much worse." Overall disease severity was assessed with the Patient Global Disease Status (PGDS) scale. Patients responded to a single item (Considering all the ways your fibromyalgia affects you, mark a vertical line on the scale for how well you have been doing overall during the last week) using a VAS with anchors of 0 = "very well" and 100 = "very poor." Other efficacy measures included the Short-Form 36 Health Survey (SF-36) 27 and the Brief Pain Inventory (BPI). 28 
Statistical Analyses
The safety population was defined as all patients who received Z1 dose of study medication. The analysis population was defined as patients in the safety population who had Z1 postbaseline efficacy assessment.
Safety analyses included the incidence of treatmentemergent SRd and mean changes from baseline to end of study in vital signs and clinical laboratory values, with baseline defined as the last value before first dose of openlabel study medication and end of study defined as the last available assessment for each patient. In order to adjust for the extended length of time in this study, treatment-emergent AEs per 100 patient-years at risk were also analyzed post hoc.
Analyses of clinical outcomes included mean PGIC scores and mean changes from baseline to end of study in VAS pain, PGDS, SF-36, and BPI scores, with baseline defined as the first postscreening study visit. Missing values were not imputed; analyses of efficacy outcomes were based on observed cases at each study visit. In addition, post hoc analyses were conducted to assess safety, tolerability, and efficacy in patients who reached study visits at 12, 24, and 36 to 38 months (ie, 1-, 2-, and 3-y patient cohorts). Outcomes analyzed by cohort included weekly recall VAS pain, PGDS, PGIC, SF-36, and vital signs. All data were analyzed using descriptive statistics.
RESULTS
Patients
The screened population included 1268 patients, 1024 of whom entered the study after completing a 3-or 6-month placebo-controlled study [19] [20] [21] [22] [23] ; 244 of these patients completed a placebo-controlled trial followed by a 6-to 9-month Gendreau 16, 17 (Fig. 1A) . A total of 1227 patients were enrolled in the study and included in the safety population, with 585 (47.7%) classified as study completers (Fig. 1B) . Study completers included 206 (16.8%) patients who reached the final visit at 36 to 38 months and 379 (30.9%) patients who were currently enrolled when the study was administratively terminated. The most common reason for discontinuation from the study was AE (20.9%); 31.5% of enrolled patients discontinued due to other reasons. Demographics and baseline clinical characteristics are reported in Table 1 .
The mean duration of milnacipran treatment was 563.1 days. Total exposure to milnacipran in this study was 1889.1 patient-years at risk. After dose-escalation, the mean daily dose of milnacipran was 133.7 mg/d. Mean final dose was 140.1 mg/d, with percentages of patients receiving final doses as follows: 7.2% (r50 mg/d), 33.1% (> 50 to 100 mg/d), 24 .2% (> 100 to 150 mg/d), and 35.6% (> 150 mg/d).
Almost all patients (98.8%) received at least 1 concomitant medication at some point during this long-term study. The most commonly used medications with potential analgesic effects (ie, reported in Z10% of patients) were ibuprofen (40.2%), acetaminophen (35.2%), naproxen/naproxen sodium (23.7%), acetaminophen and hydrocodone (19.2%), acetylsalicylic acid (16.2%), and cyclobenzaprine/ cyclobenzaprine hydrochloride (10.3%).
Safety and Tolerability
Treatment-emergent AE were reported in 88.3% of patients (Table 2) , with most of these events (89.5%) rated as mild or moderate in severity and the majority (64.4%) judged by investigators to be unrelated to study treatment.
Treatment-emergent AE occurring in Z10% of patients were nausea (25.9%), headache (13.4%), hypertension (11.2%), and sinusitis (10.4%) ( Table 2) . When analyzed as events per 100 patient-years at risk, the incidence rates were 16.8% for nausea and <10% for the other treatment-emergent AE. A total of 256 patients (20.9%) discontinued the study due to AE, most commonly from nausea (2.9%), hypertension (1.7%), hyperhidrosis (1.5%), hot flush (1.3%), depression (1.3%), palpitations (1.3%), and headache (1.1%). Serious AE occurred in 109 (8.9%) patients. The most common serious AE was cholelithiasis, which occurred in 7 patients (0.6%). No deaths occurred during the study.
In the overall safety population, mean increases from baseline to end of study in supine systolic blood pressure (SBP, + 4.0 mm Hg), diastolic blood pressure (DBP, + 3.3 mm Hg), and heart rate (+ 5.0 bpm) were observed, with potentially clinically significant increases in these vital signs occurring infrequently (SBP Z180 mm Hg with increase Z20 mm Hg from baseline, 0.3%; DBP Z110 mm Hg with increase Z15 mm Hg from baseline, 1.1%; heart rate Z120 bpm with increase Z20 bpm from baseline, 0.4%). In the 3-year patient cohort (n = 220), mean increases in blood pressure and heart rate remained relatively constant throughout the study, except for a larger increase in blood pressure at the final study visit ( Table 3) . Similar results were observed in the 1-year patient cohort (at 12 mo, n = 823: SBP, + 3.3 mm Hg; DBP, + 3.6 mm Hg; heart rate, + 6.4 bpm) and the 2-year patient cohort (at 24 mo, n = 462: SBP, + 3.3 mm Hg; DBP, + 2.8 mm Hg; heart rate, + 6.0 bpm).
In the safety population, mean weight change from baseline to end of study was À0.3 kg. The percentage of patients who had clinically significant weight loss (Z7% decrease from baseline) at any time during the study was 18.5%; the percentage of patients with clinically significant weight gain (Z7% increase from baseline) was 13.3%. In the 3-year cohort, mean weight loss relative to study baseline was found at 3 months (À0.79 kg) and up to 24 months (À0.58 kg), with a return toward study baseline at 30 months (À 0.03 kg) and 36 to 38 months (+ 0.31 kg). Changes in laboratory values that occurred in >2.0% of patients were eosinophils >2 times the upper limit of normal (ÂULN) (2.3%), blood urea nitrogen >1.3 ÂULN (3.2%), total cholesterol >1.6 ÂULN (2.5%), glucose >2Â ULN (3.1%), and lymphocytes <0.6 times the lower limit of normal (3.3%).
Pain, Global Status, and Functioning
Mean improvements from baseline to end of study in pain (VAS pain and BPI), overall disease severity (PGDS), and functioning (SF-36) were found for the analysis population, with generally greater mean improvements found in patients who had valid assessments at the final study visit (month 36 to 38) ( Table 4 ). Mean PGIC score at end of study was 2.2 for study completers, indicating general overall improvement in FM since the beginning of the study.
In the 3-year patient cohort, mean improvements observed at 3 months in weekly recall VAS pain (À23.1), PGDS (À22.7), and SF-36 Physical Component Summary (PCS, + 4.8) were generally maintained throughout the study and up to the final study visit (VAS pain, À23.9; PGDS, À 24.7; SF-36 PCS, + 5.4) (Fig. 2 ). In addition, the percentage of PGIC responders (ie, patients with PGIC score of 1 = much improved or 2 = very much improved) was 62.4% at 3 months; similarly high response rates were observed throughout the study, with 70.3% classified as PGIC responders at the final study visit (Fig. 3) . These results were supported by the similar trends found in the 1-and 2-year patient cohorts (Figs. 2, 3) .
DISCUSSION
This study demonstrated long-term tolerability and symptom improvements with milnacipran in patients with FM, a chronic disorder that usually requires ongoing therapy for the management of symptoms. This was the first study to evaluate the effects of a FM medication over a period of up to 3.25 years. Moreover, by optimizing dosages based on each patient's tolerability and efficacy and by allowing patients to take concomitant centrally acting analgesics, the study was designed to mimic "real-world" conditions where patients with FM most likely take multiple medications to manage their multiple symptoms and adjust dosing regimens as needed. The distribution of final daily dosages in this study (r50 mg/d, 7.2%; >50 to 100 mg/d, 33.1%; >100 to 150 mg/d, 24.2%; >150 mg/d, 35.6%) suggest that optimal dosing for milnacipran does vary among individual patients.
No new safety concerns with milnacipran were found in this long-term, open-label study. The percentage of patients reporting at least 1 treatment-emergent AE (88.3%) or discontinuing due to an AE (20.9%) was similar to results seen among milnacipran-treated patients in prior placebo-controlled FM studies in which patients received treatment for 3 or 6 months. [19] [20] [21] [22] [23] Nausea was the most common treatment-emergent AE in this study, as it was in prior studies; however, the incidence was lower (25.9%) than previously reported for milnacipran-treated patients (37%). 29 This lower incidence was expected as dosing in the present study could be adjusted for tolerability. In addition, as nausea generally occurs early during milnacipran treatment and resolves over time, 21, 22 some patients in this study might have already experienced nausea when they first received milnacipran during one of the lead-in studies and had become tolerant to these pharmacologic effects by the time they entered the present long-term study. Moreover, patients who discontinued a lead-in study due to nausea or any other reason were not included in this population of patients receiving long-term treatment. It should also be noted that although some treatment-emergent AE in this study occurred more frequently than previously reported, 29 the number of events per 100 patient-years at risk suggest that these higher incidences may reflect the extended amount of time that the patients were in the study rather than an AE of milnacipran. In addition, small mean improvements in depressive symptoms were found in the overall study population and in patients reaching the last study visit (Table 4 ). Large mean changes in BDI total score were not expected as patients with major depressive episode or severe depressive symptoms were excluded from this study and from the prior milnacipran trials. Moreover, it is possible that patients who received milnacipran in a previous study experienced some improvements in mood before entering this study. 16, 21, 22 Results from this study also suggest that there is no progressive increase over time in blood pressure or heart rate among patients receiving long-term milnacipran treatment, although vital signs should be continually monitored in all patients treated with this medication. 29 The mean increases in blood pressure (up to 4.0 mm Hg) and heart rate (5 bpm) found in the safety population of this study were similar to the mean increases seen in patients receiving 3 to 6 months of milnacipran treatment in placebo-controlled studies (blood pressure, up to 3.1 mm Hg; heart rate, 7 to 8 bpm). 29 In addition, analysis by patient cohort (1, 2, and 3 y) showed no notable differences among these cohorts, with the exception of a slightly greater increase in blood pressure at the final study visit in patients who received Z3 years of treatment. The long-term clinical significance of these vital sign changes is not known.
Although the primary aim of this study was to evaluate the tolerability and safety of milnacipran in patients receiving long-term treatment, the effects of milnacipran on pain, overall disease severity, and physical functioning were also evaluated. Improvements in these domains were generally observed at the first study assessment and maintained throughout the study (Fig. 2) . In patients receiving Z3 years of treatment, mean change in VAS weekly recall pain score was À 23.9 mm, representing a 38% improvement from baseline. Moreover, approximately 70% of patients rated their global improvements with milnacipran as "much improved" or "very much improved" from the beginning of this study (Fig. 3) .
A few limitations with regard to this study should be considered. First, although this study was designed to stand alone, it included patients who had participated in a previous milnacipran study. As a result, some patients entered the current study after receiving up to 15 months of prior active treatment, whereas others entered the study after having received placebo during a lead-in study. In addition, lead-in studies were completed at various times before the current study. Although the 2-week washout period at the beginning of this study was conducted to mitigate such differences, the baseline clinical characteristics seen in this patient population may reflect some residual improvements with milnacipran from previous studies. Second, a large number of patients withdrew from the study (52.3% [642/ 1227]) or were discontinued when the study was administratively terminated (30.9% [379/1227]). As might be expected in a study of this duration, the most common reasons for early discontinuation were AE, patient withdrawal of consent, and loss to follow-up. Third, because this study was designed to evaluate the effects of milnacipran in a more "real-world" setting than was allowed in prior placebo-controlled and extension studies, a few points may need to be considered when interpreting the abovereported results. Factors such as flexible dosing and allowed concomitant medication use may have had some impact (positive or negative) on study outcomes. The reasons for concomitant medication use, as well as the dosage and duration of these treatments, were not analyzed. Finally, in the absence of a placebo comparator group, conclusions from this study regarding the long-term efficacy of milnacipran are limited to changes relative to study baseline. It should be noted, however, that some patients from this study were subsequently enrolled in a randomized, placebocontrolled, withdrawal study. A preliminary report from that study indicates that FM patients who continued receiving long-term milnacipran had significantly better clinical outcomes than patients who were withdrawn from treatment. 30 
CONCLUSIONS
This study, which included patients receiving up to 3.25 years of treatment, is the first to examine the effects of a FM medication over such an extended length of time. No new safety concerns were observed in patients with FM receiving long-term milnacipran treatment, which extended beyond 3 years in some patients. Short-term improvements in pain and other symptoms seemed to be maintained over the duration of this long-term follow-up study, with 70% of patients reporting clinically significant global improvements after 3 years of treatment. These results describe the safety, tolerability, and clinical benefits of long-term milnacipran use in patients with FM.
